Cardio-oncology & otherCross-sectional study

The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011–22

Eur J Prev CardiolPublished

  • Cross-sectional study
  • multivariable logistic regression
  • average marginal effects

Authors' conclusion

Preventive pharmacological agents are underutilized in those with cancer and concomitant CVD, and physical activity is underutilized in patients with cancer in those with or without CVD.

Study context

Population
Behavioural Risk Factor Surveillance System Survey respondents, with and without cardiovascular disease (CVD) (coronary disease or stroke), 2011–22579,114 with CVD
Participants
5,012,721 respondents
Exposure
Cancer vs no cancer
  • Cancern = 842,221
Outcome
Use of preventive CV measures: pharmacological therapies, physical activity, smoking cessation, post-CVD rehabilitation (AME = average difference in probability of use, cancer vs no cancer)

Main finding

As reported in the abstract

Use of pharmacological therapies, patients with CVD

Average marginal effects (AME), %

BP-lowering medications
−1.46 (95% CI −2.19% to −0.73%)
lipid-lowering medications
−2.34 (95% CI −4.03% to −0.66%)
aspirin
−6.05 (95% CI −8.88% to −3.23%)

Observational data: associations, not effects.

Further findings

Pharmacological therapies, patients without CVD

No statistically significant differences between patients with and without cancer

Physical activity (overall cohort) and post-CVD rehabilitation

Cancer associated with significantly lower likelihood of physical activity and of post-CVD rehabilitation, particularly post-stroke rehabilitation

Original publication

The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011–22. Eur J Prev Cardiol. Published 9 May 2023. doi:10.1093/eurjpc/zwad146

Summarised from the published abstract; every number is checked against it